



Clinical Trial Details (PDF Generation Date :- Fri, 16 Apr 2021 19:59:36 GMT)

CTRI Number	CTRI/2021/01/030454 [Registered on: 14/01/2021] - Trial Registered Prospectively		
Last Modified On	13/01/2021		
Post Graduate Thesis	No		
Type of Trial	Interventional		
Type of Study	Ayurveda		
Study Design	Randomized, Parallel Group Trial		
Public Title of Study	Clinical study on Zandu Chyavanprash as a preventive remedy in pandemic of Covid-19.		
Scientific Title of Study	Clinical evaluation of Zandu Chyavanprash as an immunity booster for its preventive effect on infections in pandemic of COVID-19 – An open label, Multi centric, Randomized, Comparative, Prospective, Interventional Community based Clinical Study on Healthy individuals		
Secondary IDs if Any	Secondary ID	Identifier	
	ZCP-CVD-19/2020/01 Version 1.0 Dated 20th Dec 2020	Protocol Number	
Details of Principal Investigator or overall Trial Coordinator (multi-center study)	Details of Principal Investigator		
	Name	Dr Maheshkumar Harit	
	Designation	Dean	
	Affiliation	D. Y. Patil University School of Ayurveda Nerul	
	Address	OPD No.10 Ground Floor, Department of Kayachiktsa D. Y. Patil University School of Ayurveda Nerul, Sector 7 Navi Mumbai Mumbai (Suburban) MAHARASHTRA 400706 India	
	Phone	9322217607	
	Fax		
	Email	drmaheshkharit@rediffmail.com	
	Details Contact Person (Scientific Query)	Details Contact Person (Scientific Query)	
		Name	Dr Sanjay Tamoli
Designation		Director	
Affiliation		Target Institute of Medical Education and Research	
Address		Target Institute of Medical Education and Research Department of Medical Services, 4th Floor, A wing, 402-A/B/C, Jaswanti Allied business center Kachpada, Malad west, Mumbai Mumbai (Suburban) MAHARASHTRA 400064 India	
Phone		9322522252	
Fax			
Email		targetinstitute@yahoo.com	
Details Contact Person (Public Query)	Details Contact Person (Public Query)		
	Name	Dr Sanjay Tamoli	
	Designation	Director	
	Affiliation	Target Institute of Medical Education and Research	
	Address	Target Institute of Medical Education and Research Department of Medical Services, 4th Floor, A wing, 402-A,B,C, Jaswanti Allied business center Kachpada, Malad west, Mumbai Mumbai (Suburban) MAHARASHTRA	



	400064 India
Phone	9322522252
Fax	
Email	targetinstitute@yahoo.com
Source of Monetary or Material Support	Source of Monetary or Material Support
	> Emami Ltd, 687, Annadapur, EM Bypass, Kolkata-700107
Primary Sponsor	Primary Sponsor Details
Name	Emami Ltd
Address	687, Annadapur, EM Bypass, Kolkata-700107
Type of Sponsor	Pharmaceutical industry-Indian
Details of Secondary Sponsor	Name
	NIL
	Address
	NIL
Countries of Recruitment	List of Countries
	India
Sites of Study	Name of Principal Investigator
	Name of Site
	Site Address
	Phone/Fax/Email
	Dr Shishir Pande
	Ayurved Seva Sanghs Ayurved Mahavidyalaya
	OPD No 7A, Ground Floor, Ayurved Sanshodhan Vibhag, Ayurved Seva Sanghs Ayurved Mahavidyalaya, Ganeshwadi, Panchvati, Nashik – 422003 Nashik MAHARASHTRA
	9420830818 shishir.nsk@gmail.com
	Dr Maheshkumar Harit
	D. Y. Patil University School of Ayurveda Nerul
	OPD No.10 Ground Floor, Department of Kayachikitsa D. Y. Patil University School of Ayurveda Nerul, Sector 7 Navi Mumbai 400706 Mumbai (Suburban) MAHARASHTRA
	9322217607 drmaheshkharit@rediffmail.com
	Dr Vaishali Deshpande
	Khemdas Ayurved Hospital
	Department of Kayachikitsa, Ground Floor, OPD No. 8, Khemdas Ayurved Hospital, P.O. Ishwarpura, Tal-Waghodia, Dist-Vadodara Vadodara GUJARAT
	9096082950 dr.vaishalid@gmail.com
	Dr Pranita Deshmukh
	MAMs SS Ayurveda Mahavidyalaya and Sane Guruji Arogya Kendra
	Department of Sharir Kriya, Ground Floor, OPD No. 15, MAMs SS Ayurveda Mahavidyalaya and Sane Guruji Arogya Kendra Malwadi Hadapsar Pune 411028 Pune
	9822229579 pranitaj@gmail.com



Dr Shailesh Deshpande	Parul Ayurveda Hospital, Parul University	MAHARASHTRA Department of Kaychikitsa, OPD no 106, Ground Floor, Parul Ayurveda Hospital, Parul University, P.O.Limba, Tal. Wagholia, Dist, Vadodara, Gujrat 391760 Vadodara GUJARAT	9763104451 dr.shaileshd@gmail.com
-----------------------	---	---	--------------------------------------

Details of Ethics Committee

Name of Committee	Approval Status	Date of Approval	Is Independent Ethics Committee?
Institutional Ethics Committee –D Y Patil University, School of Ayurveda, Nerul, Mumbai	Submitted/Under Review	No Date Specified	No
Institutional Ethics Committee PIAR-IECHR	Approved	09/01/2021	No
Institutional Ethics Committee, Ayurved seva sangh Ayurved Mahavidyalaya, Nashik	Submitted/Under Review	No Date Specified	No
Institutional Review Board For Research, MAMs SS Ayurveda Mahavidyalaya & Sane Guruji Aarogya Kendra, Malwadi, Hadapsar, Pune	Submitted/Under Review	No Date Specified	No
Parul Institute of Ayurved and Researchs Institutional Ethics Committee for Human Research (PIA-IECHR	Submitted/Under Review	No Date Specified	No

Regulatory Clearance Status from DCGI

Status	Date
Not Applicable	No Date Specified

Health Condition / Problems Studied

Health Type	Condition
Healthy Human Volunteers	Immunity in Healthy Individuals

Intervention / Comparator Agent

Type	Name	Details
Intervention	Zandu Chyavanprash and Milk	Zandu Chyavanprash contains Bilva, Agnimantha, Syonaka, Patala, Gambhari, Shalaprani, Prishniparni , Brihati, Kantakari, Gokshura, Bala, Mudgaparni, Mashaparni, Karkatshringi, Tamalaki, Draksha , Jivanti, Pushkara Haritaki ,Guduchi, Vidari, Musta , Rakta Punarnava, Vasa, Kakanasika, Pippali, Sukshmaila, Riddhi &Vridhd, Meda & Mahamedha, Jivaka & Rishabhak, Kakoli &



		Kshir kakoli. Powder of the Following: Pippali , Vanshalochana, Tvak, Tvakpatra, Sukshmaila, Nagakesara , Amalaki, Til tail, Ghrita, Guda, Honey along with preservatives and excipients Dosage and Treatment Duration:Subjects will be given Zandu Chyavanprash in a dose of one teaspoonful approx.12 gm) twice daily followed by a cup of milk (Approx. 200 ml).
Comparator Agent	Milk	Milk Dosage and Treatment Duration: Subjects will be asked to take a cup of milk twice daily (Approx. 200 ml) and will not be given any intervention

Inclusion Criteria

Inclusion Criteria	
Age From	18.00 Year(s)
Age To	70.00 Year(s)
Gender	Both
Details	1. Healthy individuals will be considered as those who do not have any acute medical condition or chronic medical or surgical condition that requires either immediate or continuous medical monitoring or treatment. 2. Subjects tested Negative for total antibodies for COVID-19 3. Subjects who are ready to provide written informed consent and who are ready to willingly participate and follow the protocol requirements of the clinical study.

Exclusion Criteria

Exclusion Criteria	
Details	1.Pregnant and Lactating females 2. Subjects who have been confirmed of having COVID-19 and have been isolated for its treatment. Subjects having recently suffered and recovered of COVID-19 will also be excluded from the study 3. Known cases of Diabetes 4. Subjects having any medical or surgical condition that would require immediate medical or surgical intervention at the time of screening 4. Subjects having immune compromised status like HIV, Hepatitis, Tuberculosis and Cancer etc. 5. Subjects taking steroid treatment and or any kind of immunosuppressive therapy 6. Subjects participating in any other clinical study or having participated in any other study 3 months prior to screening in the present study. 7. Subjects having a past history of allergy to Chyawanprash like products 8. Other conditions, which in the opinion of the investigators makes the patient unsuitable for enrolment or could interfere in adherence to of the study protocol

Method of Generating Random Sequence

Computer generated randomization

Method of Concealment

Not Applicable

Blinding/Masking

Open Label

Primary Outcome

Outcome	Timepoints
---------	------------



	<p>1. Change in incidence of COVID-19 [by RT-PCR and or total antibody for [COVID-19] in subjects taking Zandu Chyavanprash and those not taking it</p> <p>2. Change in incidence of other non COVID-19 infections in subjects taking Zandu Chyavanprash and those not taking it</p>	<p>Screening visit (day -5), baseline visit (day 0), day 15, day 30, day 45, day 60, day 75 and day 90.</p>				
Secondary Outcome	<table border="1"> <thead> <tr> <th data-bbox="391 421 933 465">Outcome</th> <th data-bbox="933 421 1457 465">Timepoints</th> </tr> </thead> <tbody> <tr> <td data-bbox="391 465 933 835"> <p>1. Change in severity of COVID-19 (when it occurs) between two groups</p> <p>2. Change in number of subjects requiring hospitalization etc between two groups.</p> <p>3. Change in ordinal scale for clinical improvement of COVID-19 between two groups</p> <p>4. Change in incidence and severity of other allergy related health between two groups</p> <p>5. Changes in Quality of life between two groups</p> <p>6. Change in global assessment for overall change as per the investigator</p> <p>7. AE and SAE assessment</p> </td> <td data-bbox="933 465 1457 835"> <p>Screening visit (day -5), baseline visit (day 0), day 15, day 30, day 45, day 60, day 75 and day 90.</p> </td> </tr> </tbody> </table>	Outcome	Timepoints	<p>1. Change in severity of COVID-19 (when it occurs) between two groups</p> <p>2. Change in number of subjects requiring hospitalization etc between two groups.</p> <p>3. Change in ordinal scale for clinical improvement of COVID-19 between two groups</p> <p>4. Change in incidence and severity of other allergy related health between two groups</p> <p>5. Changes in Quality of life between two groups</p> <p>6. Change in global assessment for overall change as per the investigator</p> <p>7. AE and SAE assessment</p>	<p>Screening visit (day -5), baseline visit (day 0), day 15, day 30, day 45, day 60, day 75 and day 90.</p>	
Outcome	Timepoints					
<p>1. Change in severity of COVID-19 (when it occurs) between two groups</p> <p>2. Change in number of subjects requiring hospitalization etc between two groups.</p> <p>3. Change in ordinal scale for clinical improvement of COVID-19 between two groups</p> <p>4. Change in incidence and severity of other allergy related health between two groups</p> <p>5. Changes in Quality of life between two groups</p> <p>6. Change in global assessment for overall change as per the investigator</p> <p>7. AE and SAE assessment</p>	<p>Screening visit (day -5), baseline visit (day 0), day 15, day 30, day 45, day 60, day 75 and day 90.</p>					
Target Sample Size	<p>Total Sample Size=300 Sample Size from India=300 Final Enrollment numbers achieved (Total)=Applicable only for Completed/Terminated trials Final Enrollment numbers achieved (India)=Applicable only for Completed/Terminated trials</p>					
Phase of Trial	Phase 2/ Phase 3					
Date of First Enrollment (India)	22/01/2021					
Date of First Enrollment (Global)	No Date Specified					
Estimated Duration of Trial	<p>Years=0 Months=8 Days=0</p>					
Recruitment Status of Trial (Global)	Not Applicable					
Recruitment Status of Trial (India)	Not Yet Recruiting					
Publication Details	Not yet done					
Brief Summary	<p>It is an open label, multi centric, randomized, comparative, prospective, interventional, community based, clinical study on healthy individuals to evaluate efficacy and safety of Zandu Chyavanprash as an immunity booster for its preventive effect on infections in pandemic of COVID-19. The study will be carried out at 5 centres in India. As per computer generated randomization list, subjects will be divided in group A or group B. Subjects in group A will be given Zandu Chyavanprash in a dose of one teaspoonful approx.12 gm) twice daily followed by a cup of milk (Approx. 200 ml). Subjects in Group B will be asked to take a cup of milk twice daily (Approx. 200 ml) and will not be given any intervention. The primary objectives of the study will be to assess comparative incidence of COVID-19 [by RT- PCR and/or total antibody for [COVID-19] in subjects taking Zandu Chyavanprash and those not taking it over a period of 3 months (90 days) and comparative incidence of other non COVID-19 infections in subjects taking Zandu Chyavanprash and those not taking it</p>					



over a period of 3 months (90 days). The secondary objectives will be comparative assessment of severity of COVID-19 (when it occurs) in subjects taking Zandu Chyavanprash and those not taking it, comparative assessment of number of subjects requiring hospitalization, number of days of hospitalization, number of subjects requiring ICU admission and number of subjects requiring Ventilator support and mortality rate, comparative assessment of subjects in the two groups diagnosed with COVID-19 as per the ordinal scale for clinical improvement of COVID-19 published by WHO, comparative assessment of incidence and severity of other allergy related health problems like cough, sneezing, rhinitis, sore throat etc, comparative assessment of changes in Quality of life on WHO –BREF, global assessment for overall change as per the investigator (Efficacy assessment) and safety assessment by evaluation of occurrence of AE/SAE on screening visit (day -5), baseline visit (day 0), day 15, day 30, day 45, day 60, day 75 and day 90.